Cullinan Therapeutics, Inc. CGEM
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is an oncology drug developer. Its lead program, zipalertinib (CLN-081/TAS6417), is in Phase 3 for EGFR exon 20 insertion NSCLC, previously treated. Its next catalyst on record is CLN-049: Clinical data update from dose escalation (December 2026).
Upcoming catalysts
- December 2026CLN-049 — Clinical data update from dose escalation
Oncology CLN-049 • The Company plans to share updated data from the dose escalation portion of its ongoing Phase 1 trial of CLN-049 in patients with relapsed/refractory acute myeloid leukemia in December.
- December 2026CLN-978 — Initial Sjogren's disease data
Immunology CLN-978 • The Company plans to share both multi-dose and single target dose regimen data from each of its ongoing Phase 1 clinical trials of CLN-978 in December.
- February 27, 2027zipalertinib — FDA PDUFA target action date for NDA
The U.S. FDA assigned a Prescription Drug User Fee Act target action date of February 27, 2027.
- February 27, 2027zipalertinib monotherapy — NDA for zipalertinib monotherapy in second-line EGFR ex20ins NSCLC remains under FDA review with PDUFA date of February 27, 2027.
An NDA seeking accelerated approval for zipalertinib monotherapy in this indication remains under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of February 27, 2027.
- February 27, 2027zipalertinib (CLN-081/TAS6417) monotherapy — NDA for zipalertinib monotherapy in second-line EGFR exon 20 insertion NSCLC remains under FDA review with PDUFA target action date of February 27, 2027.
An NDA seeking accelerated approval for zipalertinib monotherapy in this indication remains under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of February 27, 2027.
- February 2027zipalertinib monotherapy — NDA seeking accelerated approval for zipalertinib monotherapy in second-line EGFR exon 20 insertion NSCLC remains under FDA review with PDUFA target action date of February 27, 2027.
An NDA seeking accelerated approval for zipalertinib monotherapy in this indication remains under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of February 27, 2027.
- February 2027zipalertinib — NDA for zipalertinib monotherapy in second-line EGFR exon 20 insertion NSCLC remains under FDA review with PDUFA target action date of February 27, 2027.
An NDA seeking accelerated approval for zipalertinib monotherapy in this indication remains under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of February 27, 2027.
- February 2027zipalertinib monotherapy — PDUFA target action date for zipalertinib monotherapy NDA remains February 27, 2027.
An NDA seeking accelerated approval for zipalertinib monotherapy in this indication remains under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of February 27, 2027.
Next further out: CLN-049 — Initiate Phase 1/2 combination with venetoclax and azacitidine (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| zipalertinib (CLN-081) - NDA, 2L+ EGFR ex20ins NSCLC | EGFR ex20ins NSCLC (post-platinum) | small molecule | Phase 3 |
| zipalertinib REZILIENT3 (with chemotherapy, 1L) | 1L EGFR ex20ins NSCLC | small molecule | Phase 3 |
| CLN-978 (CD19xCD3 T cell engager) | SLE, RA, Sjogren's disease | antibody | Phase 1 |
| CLN-049 (FLT3xCD3 T cell engager) | relapsed/refractory AML, MDS | antibody | Phase 1 |
| Velinotamig (BCMAxCD3 T cell engager) | autoimmune diseases (SLE; autoimmune cytopenias) | antibody | Phase 1 |
Recent results and decisions
- Oct 2, 2026met Phase 3 REZILIENT3 trial met its primary endpoint demonstrating statistically significant and clinically meaningful improvement in median progression-free survival for zipalertinib plus chemotherapy versus chemotherapy alone.
The Phase 3 REZILIENT3 trial, which met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in median progression-free survival for zipalertinib plus chemotherapy compared to chemotherapy alone.
Filing - Oct 1, 2026submitted NDA submission initiated under FDA Real-Time Oncology Review for 1L zipalertinib plus chemotherapy; completion expected by year-end 2026.
Completion of the NDA submission is expected by year-end 2026.
Filing - Aug 12, 2026met Met primary endpoint of PFS at planned interim analysis (statistically significant, clinically meaningful improvement; numbers not given); IDMC recommended unblinding.
In this analysis, the study demonstrated a statistically significant and clinically meaningful improvement in PFS in the zipalertinib containing arm.
Filing
5 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.